Journal: International Journal of Nanomedicine

Article Title: Delivery of miR-26a-5p by Subcutaneous Adipose Tissue-Derived Extracellular Vesicles Alleviates Acute Lung Injury in Mice Through CHUK/NF-κB Pathway

doi: 10.2147/IJN.S514623

Figure Lengend Snippet: Characterization of SAT and SAT-EVs. (A ) Schematic illustration of SAT-EVs extraction. ( B ) Subcutaneous adipose tissue was isolated from the abdominal region of mice. ( C ) NTA of SAT-EVs showing the size distribution and concentration. ( D ) TEM visualization showing the morphology of SAT-EVs (Scale bar = 100 nm). ( E ) WB analysis of SAT-EVs and SAT showing EV markers (Alix, CD9, Tsg101) and negative marker (Calnexin).

Article Snippet: The membranes were incubated overnight at 4 °C with primary antibodies to ensure optimal binding to target proteins, including Chuk (1:2000, ET1611-15, HUABIO, China), CD9 (1:500, ab307885, Abcam, China), IL-1β (1:1000, 31202T, CST, US), TSG101 (1:2000, ab125011, Abcam, China), Calnexin (1:1000, 66,903-1-IgG, MCE, China), GAPDH (1:1000, GB15004, Servicebio, China), iNOS (1:1000, 18,985-1-AP, Proteintech, China), Phospho-p65 (1:1000, 3033T, CST, US), p65 (1:1000, 8242T, CST, US), IκBα (1:1000, 4014T, CST, US), Phospho-IκBα (1:1000, 2859T, CST, US), and PTGS2 (1:1000, 12282T, CST, US).

Techniques: Extraction, Isolation, Concentration Assay, Marker

Journal: Frontiers in Immunology

Article Title: A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy

doi: 10.3389/fimmu.2022.1001381

Figure Lengend Snippet: The hazard rate of genes for glioma patients with IDH1mt.

Article Snippet: Primary antibodies used were as follows: HLA-DQA2 (1:200; Cat No. 42-669, ProSci, Fort Collins, CO, USA), HOXA3 (1:100; Cat No.ab230879, Abcam, Cambridge, UK), SAA2 (1:500; Cat No. CAU25292; Biomatik, Kitchener, Canada), CD8 (1:4000; Cat No. 66868-1-Ig; Proteintech, Wuhan, China), and CD86 (1:250; Cat No. ab220188, Abcam).

Techniques:

Journal: Frontiers in Immunology

Article Title: A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy

doi: 10.3389/fimmu.2022.1001381

Figure Lengend Snippet: Hub genes selected to construct the risk model. (A, B) LASSO analysis for hub genes associated with the survival rate of IDH1mt-glioma patients. (C) Multivariate Cox regression analysis of HLA-DQA2 , HOXA3 , and SAA2. These three genes were used to construct the risk model.

Article Snippet: Primary antibodies used were as follows: HLA-DQA2 (1:200; Cat No. 42-669, ProSci, Fort Collins, CO, USA), HOXA3 (1:100; Cat No.ab230879, Abcam, Cambridge, UK), SAA2 (1:500; Cat No. CAU25292; Biomatik, Kitchener, Canada), CD8 (1:4000; Cat No. 66868-1-Ig; Proteintech, Wuhan, China), and CD86 (1:250; Cat No. ab220188, Abcam).

Techniques: Construct

Journal: Frontiers in Immunology

Article Title: A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy

doi: 10.3389/fimmu.2022.1001381

Figure Lengend Snippet: Expression of HLA-DQA2 , HOXA3 , SAA2 , CD86 , and CD8 in IDH1mt-glioma tissues. IDH1mt-glioma tissues were divided into long- and short-term survival groups according to the patient’s number of days of survival with the cut-off as 15 months. (A) The IHC score of HLA-DQA2 , HOXA3 , and SAA2 in IDH1mt-glioma tissues in long- and short-term groups. (B) Representative figures of expression of HLA-DQA2 , HOXA3 , and SAA2 in long- and short-term group IDH1mt-glioma tissues. (C) Expression of CD86 and CD8 in long- and short-term group IDH1mt-glioma tissues. (D–F) The diagnostic value of HLA-DQA2 , HOXA3 , and SAA2 for distinguishing long- and short-term survival of IDH1mt-glioma patients. ** P < 0.01.

Article Snippet: Primary antibodies used were as follows: HLA-DQA2 (1:200; Cat No. 42-669, ProSci, Fort Collins, CO, USA), HOXA3 (1:100; Cat No.ab230879, Abcam, Cambridge, UK), SAA2 (1:500; Cat No. CAU25292; Biomatik, Kitchener, Canada), CD8 (1:4000; Cat No. 66868-1-Ig; Proteintech, Wuhan, China), and CD86 (1:250; Cat No. ab220188, Abcam).

Techniques: Expressing, Diagnostic Assay